Anti-human CD22/Siglec 2 Monoclonal Antibody FITC Conjugated, Flow Validated

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Boster

product type :

antibody

product name :

Anti-human CD22/Siglec 2 Monoclonal Antibody FITC Conjugated, Flow Validated

catalog :

FC01572-FITC

quantity :

100 Tests, 200 Tests

clonality :

monoclonal

host :

mouse

conjugate :

FITC

clone name :

MYG13

The same clone is also sold as:

Invitrogen: MA1-7635
Santa Cruz Biotechnology: sc-7323

reactivity :

human

application :

flow cytometry

product information

SKU :

FC01572-FITC

Product Name :

Anti-human CD22/Siglec 2 Monoclonal Antibody FITC Conjugated, Flow Validated

Size :

100 Tests, 200 Tests

Clonality :

Monoclonal

Clone Number :

MYG13

Host :

Mouse

Conjugate :

FITC

Reactivity :

Human

Application(s) :

Flow Cytometry

Application Details :

User need to optimize the dilution ratio for this antibody

Description :

Boster Bio Anti-human CD22/Siglec 2 Monoclonal Antibody FITC Conjugated, Flow Validated catalog # FC01572-FITC. Tested in Flow Cytometry applications. This antibody reacts with Human. Introduction: The clone MYG13 recognizes CD22 cell surface antigen, a 130-140kDa protein. The expression of CD22 is primarily restricted to the normal and neoplastic B cells but does not express on other haemopoietic cells. The initiation of expression of CD22 starts in the cytoplasm of pro-B and pre-B cells. Although CD22 is not expressed by plasma cells, it is abundantly expressed by the follicular mantle and marginal zone B-cells. Being a member of the immunoglobulin superfamily, CD22 serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and leukocytes. The role of CD22 in the activation of B-cells is primarily associated with tyrosine kinases mediated signal transduction pathways. This antibody is routinely tested by flow cytometric analysis. Flow cytometry and other applications were tested during antibody development by Boster or are reported in the literature. Application Information: Each lot of this antibody has been pre-titrated and tested by flow cytometric analysis of human PBMCs such that 5µl of this product is sufficient for staining of 1 million cells in a 100µl staining volume or 100µl of whole blood. It is recommended that antibody reactivity be empirically titrated for optimal performance in the application of interest.

Concentration :

0.5-1mg/ml, actual concentration vary by lot. Use suggested dilution ratio to decide dilution procedure.

Gene Name :

CD22

Uniprot ID :

P20273

Form :

Liquid

Contents :

PBS with 0.09% NaN3 and 0.2% (w/v) BSA

Isotype :

IgG1,k

Storage :

Store at 4°C for one year. Do not freeze.

Gene Full Name :

B-cell receptor CD22

Synonyms :

B-cell receptor CD22; B-lymphocyte cell adhesion molecule; BL-CAM; Sialic acid-binding Ig-like lectin 2; Siglec-2; T-cell surface antigen Leu-14; CD22; CD22; SIGLEC2;

Protein Name :

B-cell receptor CD22

Molecular Weight :

95348 MW

Protein Function :

Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

Subcellular Localization :

Cell membrane; Single-pass type I membrane protein.

Tissue Specificity :

B-lymphocytes.

Background :

CD22 or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. This gene is mapped to 19q13.2. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases. It is a negative regulator of antigen receptor signaling whose onset of expression at the mature B cell stage may serve to raise the antigen concentration threshold required for B cell triggering. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signalling. This gene can downmodulate signaling through the IgM and IgD B-cell receptors (BCRs), but not through the IgG BCR, because the IgG cytoplasmic tail prevents CD22 phosphorylation and actually enhances IgG-BCR signaling.

Research Category :

Adaptive Immunity, B Cells, Cancer, Hematopoietic Progenitors, Immunology, Lymphoid, Stem Cells, Tumor Antigens, Tumor Biomarkers, Tumor Immunology, Tumor-Associated Antigens